Sobi's Gout Drug Aced Every Test. The FDA Still Said No.

In its two Phase 3 trials, DISSOLVE I and II, roughly 51% of patients on the high dose maintained their uric acid below the critical 6 mg/dL threshold for at least 80% of month six. Both trials hit their primary endpoint. Among patients who completed all 6 doses, tophus resolution rates were 10 to 14 times higher than placebo. Flare frequency dropped over time while it actually increased in the placebo group.

The clinical story, in other words, is strong.

The Factory Problem That Won't Go Away

NASP's rejection fits a pattern that has quietly become the biggest bottleneck in drug development. It's not failing clinical trials that kills most drugs at the FDA finish line anymore. It's failing to prove you can make them reliably.

The numbers are striking. An analysis of more than 200 CRLs issued between 2020 and 2024 found that roughly 74% involved manufacturing or quality deficiencies. Facility inspections and CMC problems were cited more often than clinical safety and efficacy concerns combined. In the narrower window of January 2024 through January 2025, 56% of 89 CRLs flagged facility inspection failures specifically.

This isn't a fluke; it's the dominant trend in FDA rejections. And 2025 only intensified it. The agency issued 314 warning letters in fiscal year 2025, with over 120 going to drug manufacturing facilities for significant CGMP (current good manufacturing practice) violations. The CDER warning letter count jumped 59% compared to the prior year.

The most common violation? Failures of the quality control unit, the team responsible for ensuring every batch meets standards. Think of it as the FDA finding that the referee at your factory isn't actually watching the game.

A Who's Who of Manufacturing Rejections

Sobi is in good (or at least crowded) company. Several major drugs have hit the same wall in recent years:

• Eli Lilly's Omvoh for ulcerative colitis received a CRL tied to facility deficiencies at its Indianapolis plant.
• Regeneron's Eylea HD was blocked because manufacturing methods didn't comply with CGMP regulations.
• Novartis's Leqvio faced facility-related quality issues before eventually gaining approval.
• Ultragenyx's gene therapy UX111 got a July 2025 CRL for CMC observations the company called "readily addressable," but the delay pushed potential approval into 2026.

The pattern is consistent: strong clinical data can't compensate for a manufacturing stumble. The FDA has made it clear that how you make a drug matters just as much as whether it works.

What Happens Next for Sobi

Sobi plans to request a meeting with the FDA to clarify exactly what needs fixing. From there, the company will work with its contract manufacturers to shore up quality systems, bolster documentation, and provide the additional CMC data the agency wants. Analysts estimate that remediation and resubmission could take 6 to 12 months, though the exact timeline depends on how deep the facility issues run.

The good news for Sobi's investors: the company isn't a one-trick pony. Its rare-disease portfolio spans haematology, immunology, and specialty care, with haematology products growing about 27% at constant exchange rates in Q2 2025. At its 2026 Capital Markets Day, Sobi set a target to roughly double revenue by 2030 across six major product launches.

Analysts have mostly treated the CRL as a timing setback, not a thesis killer. The stock still carries a "buy" recommendation from covering analysts, with a price target around SEK 475. The reasoning is straightforward: the clinical data are solid, the manufacturing issues look fixable, and the broader portfolio provides a cushion.

Sobi also has a second gout asset in development. It acquired Arthrosi Therapeutics in December 2025 for $950 million upfront (plus up to $550 million in milestones), gaining pozdeutinurad, a Phase 3 oral urate-lowering drug. Two differentiated late-stage gout programs give the company options even if NASP's delay stretches longer than expected.

The Bigger Lesson

For years, biotech companies treated manufacturing as the boring back-office stuff you figure out after the exciting clinical data roll in. The FDA has flipped that script. When three out of every four rejection letters cite manufacturing problems, CMC isn't a checkbox. It's the exam.

Sobi built a drug that works beautifully in patients. Now it needs to prove it can build the drug itself, consistently and at scale. In 2026, that's not a minor detail. It's the whole ballgame.

Sarepta's Worst Week: Two Deaths, a Black Box, and 500 Pink Slips

Sarepta's Duchenne gene therapy Elevidys just got the FDA's most severe safety warning after fatal liver failures, while the company slashes 36% of its workforce and pivots away from gene therapy entirely. It's a brutal week that raises big questions about the future of the entire field.